ClinicalTrials.gg
CompletedNCT01496469Updated Aug 31, 2015Results posted

Effect of Febuxostat on Blood Pressure

A Phase 2 interventional study of Febuxostat and Placebo in Hypertension, sponsored by Takeda. Completed at 46 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-31.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Hypertension by Takeda — none open to participants now, none under way, none of them phase 3. Hypertension · Takeda.

Enrollment
23rd of 34
121 · median 383
Started
2012
with 2 others
Phase 2
4 of 44
none open now
Registered
26th of 44
by date

Among the 44 studies in Hypertension by Takeda, this one is the 23rd largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2012, is one of 4 in phase 2, and was the 26th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 44 studies in Hypertension by Takeda is open now. The open studies under Hypertension, anywhere →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies in Hypertension by Takeda as a file.
02

Study summary

The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).

Read the detailed description

This study is designed to evaluate the effect of febuxostat during 6 weeks of treatment.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has documented hypertension, defined as average clinic systolic blood pressure (SBP) of ≥145 mm Hg and ≤165 mm Hg or average clinic diastolic blood pressure (DBP) of ≥90 mm Hg and ≤105 mm Hg at the Day -21 Screening Visit; the average BP measurement at two of the three Placebo Run-in Visits (Day -14, Day -7 and Day -1) must also meet the above criteria for hypertension.
  2. The participant has a serum uric acid (sUA) level ≥7.0 mg/dL not associated with gout, at the Day -21 Screening Visit.
  3. The participant has a 24-hour mean ambulatory SBP of ≥130 mm Hg and \< 165 mm Hg at the Baseline (Day 1) Visit.
  4. At the initial Screening Visit (Day -21), the maximum number of antihypertensive medications the participant is taking is ≤ 2 (fixed-dose combination medications are considered 2 medications, including diuretics), and the participant has been on a stable dose of this medication for at least1 month prior to start of the initial Screening Visit (Day -21).
  5. The participant is male and at least 18 years of age, or a female who is:

    • Surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation), OR
    • (defined as at least 1 year since last regular menses with an follicle-stimulating hormone (FSH) >40 IU/L, or at least 5 years since last regular menses), OR
    • On hormone replacement therapy and ≥ 55 years of age.
  6. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  7. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. The participant has received any compound within 30 days, or within 5 half-lives of the compound (whichever is longer) prior to the Screening Visit.
  2. The participant has received febuxostat or any urate-lowering therapy (ULT) in a previous clinical study or as a therapeutic agent.
  3. The participant has gout, history of gout, or gout flares.
  4. The participant has secondary hyperuricemia (HPU) (e.g., due to myeloproliferative disorder, or organ transplant).
  5. The participant has known secondary hypertension of any etiology (e.g., renovascular disease, primary hyperaldosteronism, Cushing syndrome).
  6. The participant has a history, within the 6 months prior to screening, of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, or percutaneous coronary intervention.
  7. The participant has an irregular cardiac rhythm (e.g., atrial fibrillation, multifocal premature atrial contractions) which leads to difficulty with interpretation of ambulatory blood pressure monitoring (ABPM).
  8. The participant has a history of congestive heart failure, hypertensive encephalopathy, cerebrovascular accident, or .
  9. The participant has type 1 or poorly controlled type 2 diabetes mellitus (glycosylated [] >8.0%) at Screening.
  10. The participant has a history of infection with , , or .
  11. The participant has an average clinic SBP >165 mm Hg or DBP >105 mm Hg at 1 or more visits during the Placebo Run-in Period.
  12. The participant's average clinic SBP or DBP measurement that increases or decreases by >10 mm Hg between Placebo Run-in visits (Day -14 to Day -7, or Day -7 to Day -1, or Day -14 to Day -1).
  13. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  14. The participant has an (ALT) and/or aspartate aminotransferase (AST) values greater than 2.0 times the (ULN).
  15. The participant has a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol.
  16. The participant has a history of alcoholism or illicit drug abuse within 5 years prior to the Screening Visit or is currently consuming >14 alcoholic drinks per week.
  17. The participant has a known or allergies to febuxostat or any components of the formulations of this compound.
  18. The participant is taking or expected to take a medication as described in the excluded medication section.
  19. The participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to those participants with successfully resected basal cell or stage I squamous cell carcinoma of the skin.
  20. The participant's estimated (eGFR) is \<30 mL/min/1.73m3, where eGFR is calculated by the Central Laboratory using the Modification of Diet in Renal Disease (MDRD) formula at the Day -21 Screening Visit.
  21. The participant is noncompliant (\<80% or >120%) with study medication during Placebo Run-In Period.
  22. The participant has an upper arm circumference less than 24 cm or greater than 42 cm.
  23. The participant's work shift includes any hour between 11 PM (2300) to 7 AM (0700).
  24. The participant has a baseline 24-hour ABPM reading of insufficient quality (as described in Appendix F of the protocol).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Febuxostat 80 mg QD

    Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.

    Drug: Febuxostat

  • Placebo comparator
    Placebo QD

    Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.

    Drug: Placebo

Interventions

  • Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks

    Also known as: TMX-67, Uloric

  • DrugPlacebo

    Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6

    The change in 24-hour mean SBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6

    The change in 24-hour mean DBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6

  2. Change From Baseline in Serum Urate Levels at Week 6

    Time frame: Baseline and Week 6

07

Results

Posted Aug 31, 2015

Participant flow

Participants took part at 29 sites in the United States from 10 January 2012 to 04 August 2014.

Participant flow — Overall Study
MilestonePlaceboFebuxostat 80 mg
Started6061
Completed5053
Not completed108
Withdrew: Adverse event10
Withdrew: Protocol violation20
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject44
Withdrew: Bp exceeds protocol limits12
Withdrew: Other11

Outcome measures

PrimaryChange From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6

The change in 24-hour mean SBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6
millimeters of mercury (mmHg)PlaceboFebuxostat 80 mg
Baseline142.3 ± 1.21139.5 ± 1.18
Change at Week 6-3.4 ± 1.31-3.7 ± 1.27
Statistical analysis
  • Placebo vs Febuxostat 80 mg · ANCOVA · p = 0.882 (Analysis of covariance (ANCOVA) model with treatment as a factor, and the baseline value and prior use of an ARB or an ACEi as covariates.) · Least squares mean difference: -0.3 · 95% CI -3.9 to 3.4
SecondaryChange From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6

The change in 24-hour mean DBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6
mmHgPlaceboFebuxostat 80 mg
Baseline85.9 ± 1.1483.0 ± 1.11
Change at Week 6-2.7 ± 0.91-2.0 ± 0.88
Statistical analysis
  • Placebo vs Febuxostat 80 mg · ANCOVA · p = 0.613 (Tested at 5% significance level.) · Least squares mean difference: 0.6 · 95% CI -1.9 to 3.2
SecondaryChange From Baseline in Serum Urate Levels at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · mg/dL
Change From Baseline in Serum Urate Levels at Week 6
mg/dLPlaceboFebuxostat 80 mg
Baseline7.7 ± 0.147.6 ± 0.14
Change at Week 60.1 ± 0.17-3.3 ± 0.17
Statistical analysis
  • Placebo vs Febuxostat 80 mg · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Least squares mean difference: -3.4 · 95% CI -3.9 to -2.9

Adverse events

Collected over Treatment-emergent AEs are defined as any AEs, regardless of relationship to study drug, which occurs on or after the first double-blind dose date and up to 30 days after the last dose date of the double-blind study drug.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/60 (1.7%)1/60 (1.7%)
Febuxostat 80 mg—1/61 (1.6%)3/61 (4.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboFebuxostat 80 mg
Blood pressure increasedInvestigations1/600/61
Coronary artery insufficiencyCardiac disorders0/601/61
Most frequent other events
Most frequent other events
EventPlaceboFebuxostat 80 mg
ArthralgiaMusculoskeletal and connective tissue disorders1/603/61

Baseline characteristics

The Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.

Age, Continuous
Age, Continuous(years)PlaceboFebuxostat 80 mgTotal
Mean55.08 ± 10.60752.15 ± 10.46953.60 ± 10.597
Age, Customized
Age, Customized(participants)PlaceboFebuxostat 80 mgTotal
Less than (<) 45 years81422
45 - <65 years444387
Greater than or equal to (>=) 65 years8412
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFebuxostat 80 mgTotal
Female121123
Male485098
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFebuxostat 80 mgTotal
American Indian or Alaska Native011
Asian7815
Black or African American111021
White424183
More than one race011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFebuxostat 80 mgTotal
Hispanic or Latino91423
Not Hispanic or Latino514798
Region of Enrollment
Region of Enrollment(participants)PlaceboFebuxostat 80 mgTotal
United States6061121
Height
Height(centimeter (cm))PlaceboFebuxostat 80 mgTotal
Mean172.10 ± 8.564173.33 ± 9.206172.72 ± 8.878
Weight
Weight(kilogram (kg))PlaceboFebuxostat 80 mgTotal
Mean95.35 ± 21.199100.88 ± 19.49098.14 ± 20.460

7 further baseline measures are reported on the registry.

08

Study locations

46 sites
  • Foley, Alabama, United States
  • Buena Park, California, United States
  • Carmichael, California, United States
  • Fresno, California, United States
  • Irvine, California, United States
  • Lomita, California, United States
  • Paramount, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Wildomar, California, United States
  • Milford, Connecticut, United States
  • Fort Lauderdale, Florida, United States
  • Miami, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • Dunwoody, Georgia, United States
  • Roswell, Georgia, United States
  • Suwanee, Georgia, United States
  • Avon, Indiana, United States
  • Indianapolis, Indiana, United States
  • Lexington, Kentucky, United States
  • Biddeford, Maine, United States
  • Saint Peters, Missouri, United States
  • St. Louis, Missouri, United States
  • St. Peters, Missouri, United States
  • Henderson, Nevada, United States
  • Las Vegas, Nevada, United States
  • Albuquerque, New Mexico, United States
  • Glens Falls, New York, United States
  • Greensboro, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Shelby, North Carolina, United States
  • Fargo, North Dakota, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Lyndhurst, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Tipton, Pennsylvania, United States
  • Carrollton, Texas, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Burke, Virginia, United States
  • Manassas, Virginia, United States
  • Port Orchard, Washington, United States
  • Madison, Wisconsin, United States
09

References and documents

Publications

  • Gunawardhana L, McLean L, Punzi HA, Hunt B, Palmer RN, Whelton A, Feig DI. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study. J Am Heart Assoc. 2017 Nov 4;6(11):e006683. doi: 10.1161/JAHA.117.006683. PubMed 29102979 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2011
First posted
Dec 21, 2011
Start
Feb 2012
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Aug 31, 2015
Last update
Aug 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01496469
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 21, 2011
Start date
Feb 2012
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Aug 31, 2015
Last update
Aug 31, 2015

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion